MX2021004431A - Procesos novedosos. - Google Patents
Procesos novedosos.Info
- Publication number
- MX2021004431A MX2021004431A MX2021004431A MX2021004431A MX2021004431A MX 2021004431 A MX2021004431 A MX 2021004431A MX 2021004431 A MX2021004431 A MX 2021004431A MX 2021004431 A MX2021004431 A MX 2021004431A MX 2021004431 A MX2021004431 A MX 2021004431A
- Authority
- MX
- Mexico
- Prior art keywords
- novel processes
- compounds
- present
- processes
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/08—Preparation of nitro compounds by substitution of hydrogen atoms by nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/30—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds
- C07C209/32—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups
- C07C209/36—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of nitrogen-to-oxygen or nitrogen-to-nitrogen bonds by reduction of nitro groups by reduction of nitro groups bound to carbon atoms of six-membered aromatic rings in presence of hydrogen-containing gases and a catalyst
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
- C07C211/61—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton with at least one of the condensed ring systems formed by three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/455—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation with carboxylic acids or their derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
- C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
- C07C49/675—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
- C07C49/813—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen polycyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
Abstract
La presente invención se refiere a procesos de preparación de N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1 H-pirazol-3-sulfonamida y sales de esta. La presente invención se refiere además a composiciones farmacéuticas que comprenden esos compuestos y al uso de esos compuestos en el tratamiento y la prevención de trastornos y enfermedades médicas, más especialmente mediante la inhibición de NLRP3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1817038.1A GB201817038D0 (en) | 2018-10-19 | 2018-10-19 | Novel processes |
PCT/EP2019/078325 WO2020079207A1 (en) | 2018-10-19 | 2019-10-18 | Novel processes |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021004431A true MX2021004431A (es) | 2021-07-06 |
Family
ID=64453844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021004431A MX2021004431A (es) | 2018-10-19 | 2019-10-18 | Procesos novedosos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US11724988B2 (es) |
EP (1) | EP3867231B1 (es) |
JP (1) | JP2022505189A (es) |
KR (1) | KR20210081363A (es) |
CN (1) | CN112839927A (es) |
AR (1) | AR116753A1 (es) |
AU (1) | AU2019361274A1 (es) |
BR (1) | BR112021007428A2 (es) |
CA (1) | CA3115185A1 (es) |
GB (1) | GB201817038D0 (es) |
IL (1) | IL282166A (es) |
MX (1) | MX2021004431A (es) |
TW (1) | TW202016077A (es) |
UY (1) | UY38425A (es) |
WO (1) | WO2020079207A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
MX2020001778A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida. |
EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
JP2020531453A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | Nlrp3阻害剤としてのスルホニルウレアおよびスルホニルチオウレア |
UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
US11530200B2 (en) | 2018-03-02 | 2022-12-20 | Inflazome Limited | Compounds |
US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
PE20211049A1 (es) | 2018-07-20 | 2021-06-04 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
AU2022300325A1 (en) | 2021-06-23 | 2023-11-02 | F. Hoffmann-La Roche Ag | Process for the preparation of nlrp3 inhibitors |
WO2023156311A1 (en) | 2022-02-15 | 2023-08-24 | F. Hoffmann-La Roche Ag | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0660176B2 (ja) * | 1984-03-22 | 1994-08-10 | 日産化学工業株式会社 | ピラゾールスルホニルウレア誘導体、製法および選択性除草剤 |
GB9609641D0 (en) * | 1996-05-09 | 1996-07-10 | Pfizer Ltd | Compounds useful in therapy |
JP5729564B2 (ja) * | 2009-11-04 | 2015-06-03 | 日産化学工業株式会社 | スルホニルウレア化合物の結晶形およびその製造方法 |
WO2014002111A1 (en) * | 2012-06-26 | 2014-01-03 | Rallis India Limited | Process of preparation of azimsulfuron |
CN112250627B (zh) * | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
EP3578547B1 (en) | 2015-02-16 | 2021-05-26 | The University of Queensland | Sulfonylureas and related compounds and use of same |
EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
CA3047336A1 (en) * | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
-
2018
- 2018-10-19 GB GBGB1817038.1A patent/GB201817038D0/en not_active Ceased
-
2019
- 2019-10-18 BR BR112021007428-7A patent/BR112021007428A2/pt not_active Application Discontinuation
- 2019-10-18 EP EP19795474.6A patent/EP3867231B1/en active Active
- 2019-10-18 KR KR1020217014396A patent/KR20210081363A/ko unknown
- 2019-10-18 CN CN201980067167.0A patent/CN112839927A/zh active Pending
- 2019-10-18 TW TW108137690A patent/TW202016077A/zh unknown
- 2019-10-18 AU AU2019361274A patent/AU2019361274A1/en not_active Abandoned
- 2019-10-18 JP JP2021521138A patent/JP2022505189A/ja active Pending
- 2019-10-18 UY UY0001038425A patent/UY38425A/es unknown
- 2019-10-18 WO PCT/EP2019/078325 patent/WO2020079207A1/en unknown
- 2019-10-18 US US17/286,380 patent/US11724988B2/en active Active
- 2019-10-18 AR ARP190102967A patent/AR116753A1/es unknown
- 2019-10-18 CA CA3115185A patent/CA3115185A1/en active Pending
- 2019-10-18 MX MX2021004431A patent/MX2021004431A/es unknown
-
2021
- 2021-04-08 IL IL282166A patent/IL282166A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR116753A1 (es) | 2021-06-09 |
US20220064125A1 (en) | 2022-03-03 |
EP3867231A1 (en) | 2021-08-25 |
EP3867231B1 (en) | 2024-05-01 |
US11724988B2 (en) | 2023-08-15 |
IL282166A (en) | 2021-05-31 |
UY38425A (es) | 2020-05-29 |
CN112839927A (zh) | 2021-05-25 |
KR20210081363A (ko) | 2021-07-01 |
JP2022505189A (ja) | 2022-01-14 |
GB201817038D0 (en) | 2018-12-05 |
CA3115185A1 (en) | 2020-04-23 |
WO2020079207A1 (en) | 2020-04-23 |
BR112021007428A2 (pt) | 2021-08-03 |
TW202016077A (zh) | 2020-05-01 |
AU2019361274A1 (en) | 2021-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021004431A (es) | Procesos novedosos. | |
MX2020011196A (es) | Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida. | |
MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
MX2021004110A (es) | Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina. | |
WO2017053868A8 (en) | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses | |
EA202190960A1 (ru) | Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30) | |
WO2016109217A3 (en) | Btk inhibitors | |
PH12021550872A1 (en) | Therapeutic compounds | |
WO2017134685A3 (en) | Novel hydrazino compounds as btk inhibitors | |
EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
MX2021009539A (es) | Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
MX2022000712A (es) | Moduladores de nlrp3. | |
PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
PH12019501642A1 (en) | Novel compounds and their use in the treatment of schistosomiasis | |
PH12017501668A1 (en) | Bace1 inhibitors | |
PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease | |
ZA202100955B (en) | Thrombin inhibitors, formulations, and uses thereof | |
PH12021550258A1 (en) | Cdk8/19 inhibitors | |
PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
PH12020500120A1 (en) | Pharmaceutical compositions | |
MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. |